

Biocell Ltd announced US patent grant

Biocell Ltd announces it was granted a US patent by the US PTO for 'Composition for the treatment of urinary tract infections'.

LONDON, UNITED KINGDOM, February 14, 2023
/EINPresswire.com/ -- [Biocell](#) Ltd, announced it was granted a US Patent.



The biotech company engaged in discovery and development of several Phyto based OTC products for women's health, announced it was granted a US patent by the United State Patent and Trademark Office for 'Composition for the treatment of urinary tract infections'.

It is the second patent granted for this pharmaceutical composition, and it follows the granting of a UK Intellectual Property Office.

“

UTI is very prevalent among women of all ages. As a herbal complex, URALIX represents a new solution doesn't cause yeast infections or antibiotic resistance.”

Prof. Eyal Schiff MD, OB-GYN

Founded by Dr Laura Mann Kevehazi, a medical researcher and patented inventor: 'Biocell capitalizes on our long term research in preventive health; we are working on several IP backed formulations addressing unmet needs in urinary, breast and prostate health conditions affecting large demographics.

Our focus is shifting the paradigm from sick care to healthcare, enabling every person to take a proactive role

in their health'

As many as 60% of women experience lower urinary tract infections during their lives, in particular post menopause. Due to increasing antibiotic resistance, the majority of UTI causing bacteria are resistant to one antibiotic, with almost [80% resistant to at least two antibiotics](#), resulting in approximately [20-30% of sepsis cases originating in the urinary tract](#). This affects in particular women from disadvantaged socio-economic groups with limited access to healthcare.

According to World Health Organisation: 'Antibiotic resistance is one of the biggest threats to global health, can affect anyone, of any age, in any country' <https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance>.

Professor Dame Sally Davis, UK Special Envoy for Antimicrobial Resistance emphasizes the overuse of antibiotics is 'leading us down a path of disaster' There is an urgent unmet need to address antibiotic resistant UTIs.

Available under the registered trademark URALIX, it is manufactured in the UK and distributed under exclusive UK license by Blue Green Health Ltd. URALIX offers an alternative approach to antibiotic resistant, recurring urinary tract infection, as well as cases of allergy to antibiotics for both women and men. It can be taken long term to protect the urinary tract in people at menopause or at risk of chronic, recurring urinary symptoms.

BIOCELL is currently looking for an exclusive partner to license the manufacturing and distribution in the US and Latin America, as well as a partner for the Middle East markets.

BIOCELL is a woman founder biotech focused on discovery, preclinical studies, and development of innovative Phyto based products for conditions affecting people of all ages, ethnicity, and socio-economic group.

Laura Mann Kevehazi
BIOCELL LTD
+44 7504 947099
contact@biocellhealth.co.uk

This press release can be viewed online at: <https://www.einpresswire.com/article/616647859>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.